{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T23:07:55Z","timestamp":1769382475440,"version":"3.49.0"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1097\/md.0000000000002388","type":"journal-article","created":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T18:40:24Z","timestamp":1451414424000},"page":"e2388","source":"Crossref","is-referenced-by-count":28,"title":["Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas"],"prefix":"10.1097","volume":"94","author":[{"given":"Ana-Iris","family":"Schiefer","sequence":"first","affiliation":[]},{"given":"Christoph","family":"Kornauth","sequence":"additional","affiliation":[]},{"given":"Ingrid","family":"Simonitsch-Klupp","sequence":"additional","affiliation":[]},{"given":"Cathrin","family":"Skrabs","sequence":"additional","affiliation":[]},{"given":"Eva Katharina","family":"Masel","sequence":"additional","affiliation":[]},{"given":"Berthold","family":"Streubel","sequence":"additional","affiliation":[]},{"given":"Katrina","family":"Vanura","sequence":"additional","affiliation":[]},{"given":"Karin","family":"Walter","sequence":"additional","affiliation":[]},{"given":"Brigitta","family":"Migschitz","sequence":"additional","affiliation":[]},{"given":"Dagmar","family":"Stoiber","sequence":"additional","affiliation":[]},{"given":"Veronika","family":"Sexl","sequence":"additional","affiliation":[]},{"given":"Markus","family":"Raderer","sequence":"additional","affiliation":[]},{"given":"Andreas","family":"Chott","sequence":"additional","affiliation":[]},{"given":"Maria Gomes","family":"da Silva","sequence":"additional","affiliation":[]},{"given":"Jose","family":"Cabecadas","sequence":"additional","affiliation":[]},{"given":"Leonhard","family":"M\u00fcllauer","sequence":"additional","affiliation":[]},{"given":"Ulrich","family":"J\u00e4ger","sequence":"additional","affiliation":[]},{"given":"Edit","family":"Porpaczy","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"key":"R1-36-20210309","first-page":"987","article-title":"The International Non-Hodgkins Lymphoma Prognostic Factors Project.","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"R2-36-20210309","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nrclinonc.2013.197","article-title":"Diffuse large B-cell lymphoma-treatment approaches in the molecular era","volume":"11","author":"Roschewski","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"R3-36-20210309","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","article-title":"Double-hit B-cell lymphomas","volume":"117","author":"Aukema","year":"2011","journal-title":"Blood"},{"key":"R4-36-20210309","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/PAP.0b013e3182169948","article-title":"MYC and aggressive B-cell lymphomas","volume":"18","author":"Slack","year":"2011","journal-title":"Adv Anat Pathol"},{"key":"R5-36-20210309","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"key":"R6-36-20210309","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2014-09-594580","article-title":"Introduction to a clinical review series on aggressive B-cell lymphoma","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"key":"R7-36-20210309","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"R8-36-20210309","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2141.2009.07739.x","article-title":"The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target","volume":"146","author":"Cheung","year":"2009","journal-title":"Br J Haematol"},{"key":"R9-36-20210309","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1182\/blood-2008-01-129783","article-title":"Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study","volume":"112","author":"Young","year":"2008","journal-title":"Blood"},{"key":"R10-36-20210309","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","article-title":"MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma","volume":"121","author":"Horn","year":"2013","journal-title":"Blood"},{"key":"R11-36-20210309","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"key":"R12-36-20210309","first-page":"8","article-title":"Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma.","volume":"1-","author":"Fiskvik","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"R13-36-20210309","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/PAS.0b013e31826cebad","article-title":"Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas","volume":"37","author":"Pillai","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"R14-36-20210309","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1182\/blood-2013-05-498329","article-title":"Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification","volume":"122","author":"Ott","year":"2013","journal-title":"Blood"},{"key":"R15-36-20210309","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1053\/j.seminhematol.2013.09.004","article-title":"Newly identified mechanisms in B-cell non-Hodgkin lymphomas uncovered by next-generation sequencing","volume":"50","author":"Morin","year":"2013","journal-title":"Semin Hematol"},{"key":"R16-36-20210309","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1182\/blood-2013-02-483727","article-title":"Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing","volume":"122","author":"Morin","year":"2013","journal-title":"Blood"},{"key":"R17-36-20210309","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1200\/JCO.2012.43.5800","article-title":"Double-hit diffuse large B-cell lymphoma","volume":"30","author":"Friedberg","year":"2012","journal-title":"J Clin Oncol"},{"key":"R18-36-20210309","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/2040620712464508","article-title":"Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma","volume":"4","author":"Dunleavy","year":"2013","journal-title":"Ther Adv Hematol"},{"key":"R19-36-20210309","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1182\/asheducation-2011.1.506","article-title":"Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification","volume":"2011","author":"Jaffe","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R20-36-20210309","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/bjh.13276","article-title":"A clinician's guide to double hit lymphomas","volume":"168","author":"Cheah","year":"2015","journal-title":"Br J Haematol"},{"key":"R21-36-20210309","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.leukres.2008.06.022","article-title":"TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype","volume":"33","author":"Zainuddin","year":"2009","journal-title":"Leuk Res"},{"key":"R22-36-20210309","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1046\/j.1365-2141.1997.2403057.x","article-title":"The clinical significance of mutations of the P53 tumour suppressor gene in haematological malignancies","volume":"98","author":"Preudhomme","year":"1997","journal-title":"Br J Haematol"},{"key":"R23-36-20210309","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/sj.leu.2403206","article-title":"Diffuse large B-cell lymphomas with plasmablastic\/plasmacytoid features are associated with TP53 deletions and poor clinical outcome","volume":"18","author":"Simonitsch-Klupp","year":"2004","journal-title":"Leukemia"},{"key":"R24-36-20210309","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1038\/sj.onc.1205322","article-title":"Tumor suppressor genes in normal and malignant hematopoiesis","volume":"21","author":"Krug","year":"2002","journal-title":"Oncogene"},{"key":"R25-36-20210309","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1002\/cncr.27396","article-title":"Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab","volume":"118","author":"Akyurek","year":"2012","journal-title":"Cancer"},{"key":"R26-36-20210309","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/10428194.2014.907896","article-title":"TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations","volume":"56","author":"Gebauer","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"R27-36-20210309","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.bcmd.2010.08.002","article-title":"The impact of MYC expression in lymphoma biology: beyond Burkitt lymphoma","volume":"45","author":"Smith","year":"2010","journal-title":"Blood Cells Mol Dis"},{"key":"R28-36-20210309","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/PAS.0b013e3181cd3aeb","article-title":"B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma","volume":"34","author":"Snuderl","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R29-36-20210309","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.humpath.2009.10.027","article-title":"B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology","volume":"41","author":"Carbone","year":"2010","journal-title":"Hum Pathol"},{"key":"R30-36-20210309","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Green","year":"2012","journal-title":"J Clin Oncol"},{"key":"R31-36-20210309","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clin Oncol"},{"key":"R32-36-20210309","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1182\/blood-2013-01-480392","article-title":"MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future?","volume":"121","author":"Thieblemont","year":"2013","journal-title":"Blood"},{"key":"R33-36-20210309","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3324\/haematol.11305","article-title":"The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24\/c-MYC rearrangement","volume":"92","author":"Le Gouill","year":"2007","journal-title":"Haematologica"},{"key":"R34-36-20210309","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/asheducation-2014.1.107","article-title":"Double-hit lymphomas: current paradigms and novel treatment approaches","volume":"2014","author":"Dunleavy","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R35-36-20210309","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/leu.2015.43","article-title":"Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma","volume":"29","author":"Horn","year":"2015","journal-title":"Leukemia"},{"key":"R36-36-20210309","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3324\/haematol.2012.066209","article-title":"Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study","volume":"98","author":"Visco","year":"2013","journal-title":"Haematologica"},{"key":"R37-36-20210309","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1309\/AJCPPHMZ6VHF0WQV","article-title":"p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study","volume":"141","author":"Xie","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"R38-36-20210309","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2010-10-313098","article-title":"The cooperating mutation or \u201csecond hit\u201d determines the immunologic visibility toward MYC-induced murine lymphomas","volume":"118","author":"Schuster","year":"2011","journal-title":"Blood"},{"key":"R40-36-20210309","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/(SICI)1096-9896(200003)190:4<450::AID-PATH545>3.0.CO;2-8","article-title":"Staining patterns of p53 immunohistochemistry and their biological significance in colorectal cancer","volume":"190","author":"Kaserer","year":"2000","journal-title":"J Pathol"},{"key":"R41-36-20210309","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/01.pas.0000155163.40668.e7","article-title":"Genetic aberrations in primary cutaneous large B-cell lymphoma: a fluorescence in situ hybridization study of 25 cases","volume":"29","author":"Wiesner","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"R42-36-20210309","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study","volume":"120","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"key":"R43-36-20210309","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/PAP.0b013e3182a289f2","article-title":"MYC\/BCL2 double-hit high-grade B-cell lymphoma","volume":"20","author":"Li","year":"2013","journal-title":"Adv Anat Pathol"},{"key":"R44-36-20210309","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/modpathol.2011.147","article-title":"B-cell lymphomas with MYC\/8q24 rearrangements and IGH@BCL2\/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome","volume":"25","author":"Li","year":"2012","journal-title":"Mod Pathol"},{"key":"R45-36-20210309","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/leu.2008.344","article-title":"Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24\/c-MYC translocations","volume":"23","author":"Niitsu","year":"2009","journal-title":"Leukemia"},{"key":"R46-36-20210309","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cancergen.2014.02.001","article-title":"BCL2, BCL6, IGH, TP53, and MYC protein expression and gene rearrangements as prognostic markers in diffuse large B-cell lymphoma: a study of 44 Turkish patients","volume":"207","author":"Akay","year":"2014","journal-title":"Cancer Genet"},{"key":"R47-36-20210309","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/annonc\/mdf185","article-title":"p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas","volume":"13","author":"Leroy","year":"2002","journal-title":"Ann Oncol"},{"key":"R48-36-20210309","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2559.2008.03076.x","article-title":"MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type","volume":"53","author":"Yoon","year":"2008","journal-title":"Histopathology"},{"key":"R49-36-20210309","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1038\/leu.2008.230","article-title":"Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)","volume":"22","author":"Klapper","year":"2008","journal-title":"Leukemia"},{"key":"R50-36-20210309","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","author":"Savage","year":"2009","journal-title":"Blood"},{"key":"R51-36-20210309","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Barrans","year":"2010","journal-title":"J Clin Oncol"},{"key":"R52-36-20210309","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1093\/annonc\/mdu109","article-title":"Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era","volume":"25","author":"Vaidya","year":"2014","journal-title":"Ann Oncol"},{"key":"R53-36-20210309","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.1200\/JCO.2005.05.012","article-title":"Molecular pathogenesis of diffuse large B-cell lymphoma","volume":"23","author":"Lossos","year":"2005","journal-title":"J Clin Oncol"},{"key":"R54-36-20210309","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1038\/onc.2009.46","article-title":"Noxa: at the tip of the balance between life and death","volume":"27","author":"Ploner","year":"2008","journal-title":"Oncogene"},{"key":"R55-36-20210309","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood-2008-03-145128","article-title":"A prospective clinicopathologic study of dose-modified CODOX-M\/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial)","volume":"112","author":"Mead","year":"2008","journal-title":"Blood"},{"key":"R56-36-20210309","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","article-title":"Low-intensity therapy in adults with Burkitt's lymphoma","volume":"369","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"key":"R57-36-20210309","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1200\/JCO.2007.13.1391","article-title":"Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers","volume":"26","author":"Wilson","year":"2008","journal-title":"J Clin Oncol"},{"key":"R60-36-20210309","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00277-013-1684-6","article-title":"Functional inhibition of BCL2 is needed to increase the susceptibility to apoptosis to SMO inhibitors in diffuse large B-cell lymphoma of germinal center subtype","volume":"92","author":"Kunkalla","year":"2013","journal-title":"Ann Hematol"},{"key":"R61-36-20210309","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000002388","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:57:17Z","timestamp":1620961037000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201512280-00036"}},"subtitle":["A Retrospective Cohort Study"],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":58,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000002388","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}